Clinical Evaluation of Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on Peripheral Blood Recovery after Allogeneic Bone Marrow Transplantation in Children with Malignant Disorders.
スポンサーリンク
概要
- 論文の詳細を見る
We analyzed the clinical effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in allogeneic bone marrow transplanted children. The median period required for neutrophil recovery (> 500/μl) was markedly shortened by the rhG-CSF treatment : 21 days in the rhG-CSF group (<I>n</I>=11) versus 27 days in the historical control group (<I>n</I>=12). We found no effects on recovery of other blood cell series. However, the mean neutrophil counts and frequency of neutropenic patients at day 11 and day 15 after BMT were not significantly different in both groups. These results suggest that rhG-CSF does not contribute to neutrophil recovery in very early posttransplant period. It may be necessary to evaluate further on ideal time for starting rhG-CSF in children who undergo allogeneic bone marrow transplantation.
- 特定非営利活動法人 日本小児血液・がん学会の論文
特定非営利活動法人 日本小児血液・がん学会 | 論文
- The Parent's Emotional Adaptation to the Children's Malignant Disease
- Side Effect of Cranial Radiation in Childhood Acute Leukemia
- Red Blood Cell Volume Distribution Width in Normal Children and in the Patients with Various Kinds of Hematological Disorders.
- Effective Conditioning of Donors for Granulocyte Transfusions with Recombinant Human Granulocyte Colony-Stimulating Factor.
- Two Infant Girls of CNS Leukemia with Chronic Subdural Hematoma